Drug Profile
Enrasentan
Alternative Names: SB 217242Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Anti-ischaemics; Carboxylic acids; Heart failure therapies; Indans
- Mechanism of Action Endothelin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Heart failure; Pulmonary hypertension; Renal failure; Reperfusion injury; Stroke
Most Recent Events
- 15 Nov 2001 Discontinued-I for Congestive heart failure in Canada (PO)
- 15 Nov 2001 Discontinued-II for Congestive heart failure in USA (PO)
- 15 Nov 2001 Discontinued-II for Pulmonary hypertension in USA (PO)